Autopsy report · NCT04067856

Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery

“Inadequate patient enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Sponsor type

University, hospital or other

Conditions

Diabetic Macular Edema; Cataract

Interventions

Bevacizumab Injection

Participants

0

Trials that died the same way

• Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens
  “Lack of patient enrollment” (93% match in meaning)
• Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use
  “Insufficient patient enrollment.” (88% match in meaning)
• Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
  “Inadequate enrollment” (86% match in meaning)
• Tracking of Lipid Lowering Therapy in Jordan
  “Inadequate enrolling numbers of patients” (84% match in meaning)
• Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population
  “Poor patient enrollment due to logistical issues” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.